Comorbidity and performance status as independent prognostic factors in patients with head and neck squamous cell carcinoma

Head and Neck

Volumn 38, Issue 5, 2016, Pages 736-742

  Wang, Jennifer R ^a   Habbous, Steven ^a   Espin Garcia, Osvaldo ^a   Chen, Duoduo ^a   Huang, Shao Hui ^b   Simpson, Colleen ^a   Xu, Wei ^a   Liu, Fei Fei ^b   Brown, Dale H ^a   Gilbert, Ralph W ^a   Gullane, Patrick J ^a   Irish, Jonathan C ^a   Goldstein, David P ^a   Liu, Geoffrey ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

comorbidity; head and neck squamous cell carcinoma; performance status; prognostic model; survival outcomes

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CHARLSON COMORBIDITY INDEX; COMORBIDITY; EASTERN COOPERATIVE ONCOLOGY GROUP SCALE; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RATING SCALE; HEAD AND NECK TUMOR; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COMORBIDITY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84933073652     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23947     Document Type: Article

References (24)

1. Cooper JS, Porter K, Mallin K, et al., National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck 2009; 31: 748-758.
2. Paleri V, Wight RG, Silver CE, et al., Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. Oral Oncol 2010; 46: 712-719.
3. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L,. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582-1587.
4. Firat S, Byhardt RW, Gore E,. Comorbidity and Karnofsky performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002; 54: 357-364.
5. Repetto L, Fratino L, Audisio RA, et al., Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20: 494-502.
6. Piccirillo JF,. Importance of comorbidity in head and neck cancer. Laryngoscope 2000; 110: 593-602.
7. Reid BC, Alberg AJ, Klassen AC, et al., Comorbidity and survival of elderly head and neck carcinoma patients. Cancer 2001; 92: 2109-2116.
8. Datema FR, Ferrier MB, van der Schroeff MP, Baatenburg de Jong RJ,. Impact of comorbidity on short-term mortality and overall survival of head and neck cancer patients. Head Neck 2010; 32: 728-736.
9. Jones AS, Fenton JE, Husband DJ,. Performance data and survival in head and neck cancer. Clin Otolaryngol Allied Sci 2000; 25: 396-403.
10. Corrêa GT, Bandeira GA, Cavalcanti BG, et al., Analysis of ECOG performance status in head and neck squamous cell carcinoma patients: association with sociodemographical and clinical factors, and overall survival. Support Care Cancer 2012; 20: 2679-2685.
11. Sadat F, Wienke A, Dunst J, Kuhnt T,. Survival of patients with head and neck cancer. Impact of physical status and comorbidities. Strahlenther Onkol 2012; 188: 62-70.
12. Wong K, Huang SH, O'Sullivan B, et al., Point-of-care outcome assessment in the cancer clinic: audit of data quality. Radiother Oncol 2010; 95: 339-343.
13. Habbous S, Chu KP, Qiu X, et al., The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a Comprehensive Cancer Centre. Cancer Epidemiol 2013; 37: 820-829.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
15. Oken MM, Creech RH, Tormey DC, et al., Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
16. Singh B, Bhaya M, Stern J, et al., Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. Laryngoscope 1997; 107 (11 Pt 1): 1469-1475.
17. Hall SF, Groome PA, Rothwell D,. The impact of comorbidity on the survival of patients with squamous cell carcinoma of the head and neck. Head Neck 2000; 22: 317-322.
18. Ferrier MB, Spuesens EB, Le Cessie S, Baatenburg de Jong RJ,. Comorbidity as a major risk factor for mortality and complications in head and neck surgery. Arch Otolaryngol Head Neck Surg 2005; 131: 27-32.
19. Gimeno-Hernández J, Iglesias-Moreno MC, Gómez-Serrano M, Carricondo F, Gil-Loyzaga P, Poch-Broto J,. The impact of comorbidity on the survival of patients with laryngeal squamous cell carcinoma. Acta Otolaryngol 2011; 131: 840-846.
20. Sanabria A, Carvalho AL, Vartanian JG, Magrin J, Ikeda MK, Kowalski LP,. Factors that influence treatment decision in older patients with resectable head and neck cancer. Laryngoscope 2007; 117: 835-840.
21. Derks W, de Leeuw RJ, Hordijk GJ,. Elderly patients with head and neck cancer: the influence of comorbidity on choice of therapy, complication rate, and survival. Curr Opin Otolaryngol Head Neck Surg 2005; 13: 92-96.
22. Bourhis J, Overgaard J, Audry H, et al., Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368: 843-854.
23. Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
24. Sze HC, Ng WT, Chan OS, Shum TC, Chan LL, Lee AW,. Radical radiotherapy for nasopharyngeal carcinoma in elderly patients: the importance of co-morbidity assessment. Oral Oncol 2012; 48: 162-167.